한글목차

망막질환 치료 시장 규모는 2025년 193억 6,000만 달러에서 2026년부터 2034년까지 CAGR 9.93%로 성장하여 2034년에는 453억 9,000만 달러에 달할 것으로 예측됩니다.

노화성 황반변성(AMD), 당뇨망막병증, 망막정맥폐쇄증 등 망막질환의 유병률 증가를 배경으로 망막질환 치료제 시장은 괄목할만한 성장세를 보이고 있습니다. 전 세계적으로 고령화와 당뇨병 발병률이 증가함에 따라 망막질환에 대한 효과적인 치료법에 대한 수요가 급증하고 있습니다. 의료기술의 발전과 항VEGF제, 코르티코스테로이드, 유전자 치료 등 새로운 치료법의 개발은 망막질환 관리의 패러다임을 바꾸고 있습니다. 의료 서비스 제공자들이 환자의 치료 성과 향상과 시력 유지를 위해 노력하는 가운데, 이러한 트렌드가 시장 상황을 주도할 것으로 예상됩니다.

진단 및 치료법의 혁신이 망막질환 치료 시장의 향후 전망을 형성하고 있습니다. 빛간섭단층촬영(OCT), 안저촬영 등 첨단 영상 진단 기술의 통합으로 망막질환의 정확한 진단 및 경과관찰 능력이 향상되고 있습니다. 또한, 최소침습 수술 기술과 지속형 약물전달 시스템의 등장으로 치료 효과와 환자 순응도가 개선되고 있습니다. 망막질환의 근본적인 메커니즘에 대한 연구가 진행됨에 따라 질병 진행에 관여하는 특정 경로에 작용하는 표적 치료제가 시장에 출시될 가능성이 높아지고 있습니다.

또한, 제약회사와 학계가 이 분야의 미충족 수요를 인식함에 따라 연구개발에 대한 투자 증가는 망막질환 치료제 시장에 긍정적인 영향을 미칠 것입니다. 임상시험을 추진하고 혁신적인 치료법을 안정적으로 도입하기 위해서는 안과 의사, 연구자, 이해관계자의 협력이 필수적입니다. 이러한 환경 변화에 따라 규제 당국은 새로운 치료법의 승인 절차를 간소화하여 망막질환 환자들이 효과적인 치료법에 빠르게 접근할 수 있도록 지원할 것으로 기대됩니다. 초점은 점차 망막질환 관리를 보다 광범위한 안과 의료 전략에 통합하는 데로 옮겨갈 것이며, 시력 유지에 있어 조기 발견, 환자 교육 및 지속적인 모니터링의 중요성이 강조될 것입니다.

목차

제1장 소개

제2장 주요 요약

제3장 시장 변수, 동향, 프레임워크

제4장 세계의 망막질환 치료 시장 : 유형별

제5장 세계의 망막질환 치료 시장 : 제형별

제6장 세계의 망막질환 치료 시장 : 유통 채널별

제7장 세계의 망막질환 치료 시장 : 지역별

제8장 경쟁 구도

제9장 기업 개요

영문목차

The Retinal Disorders Treatment Market size is expected to reach USD 45.39 Billion in 2034 from USD 19.36 Billion (2025) growing at a CAGR of 9.93% during 2026-2034.

The retinal disorders treatment market is experiencing significant growth, driven by the increasing prevalence of retinal diseases, such as age-related macular degeneration (AMD), diabetic retinopathy, and retinal vein occlusion. As the global population ages and the incidence of diabetes rises, the demand for effective treatment options for retinal disorders is surging. Advances in medical technology and the development of novel therapies, including anti-VEGF agents, corticosteroids, and gene therapies, are transforming the landscape of retinal disease management. This trend is expected to propel the market forward, as healthcare providers seek to improve patient outcomes and preserve vision.

Innovations in diagnostic and treatment modalities are shaping the future of the retinal disorders treatment market. The integration of advanced imaging techniques, such as optical coherence tomography (OCT) and fundus photography, is enhancing the ability to diagnose and monitor retinal conditions accurately. Additionally, the rise of minimally invasive surgical techniques and sustained-release drug delivery systems is improving treatment efficacy and patient compliance. As research continues to uncover the underlying mechanisms of retinal diseases, the market is likely to witness the introduction of targeted therapies that address specific pathways involved in disease progression.

Moreover, the retinal disorders treatment market will benefit from increased investment in research and development, as pharmaceutical companies and academic institutions recognize the unmet needs in this area. Collaborative efforts between ophthalmologists, researchers, and industry stakeholders will be essential in advancing clinical trials and ensuring the successful implementation of innovative therapies. As the landscape evolves, regulatory bodies are expected to streamline approval processes for new treatments, facilitating faster access to effective solutions for patients with retinal disorders. The focus will increasingly shift towards integrating retinal disease management into broader eye care strategies, emphasizing the importance of early detection, patient education, and ongoing monitoring in preserving vision.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Type

• Macular Degeneration
• Diabetic Retinopathy
• Others

By Dosage Form

• Gels
• Eye Solutions
• Capsules & Tablets
• Eye Drops
• Ointments

By Distribution Channel

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

COMPANIES PROFILED

• Santen Pharmaceutical Co Ltd, Regeneron Pharmaceuticals Inc, Graybug Vision Inc, Shire Takeda Pharmaceutical Company Limited, Bayer AG, Allergan plc AbbVie Inc, Genentech Inc F HoffmannLa Roche Ltd, Acucela Inc, Pfizer Inc, Kubota Pharmaceutical Holdings Co Ltd

We can customise the report as per your requriements

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL RETINAL DISORDERS TREATMENT MARKET: BY TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Type
• 4.2. Macular Degeneration Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Diabetic Retinopathy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL RETINAL DISORDERS TREATMENT MARKET: BY DOSAGE FORM 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Dosage Form
• 5.2. Gels Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Eye Solutions Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Capsules & Tablets Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Eye Drops Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.6. Ointments Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL RETINAL DISORDERS TREATMENT MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Distribution Channel
• 6.2. Hospital Pharmacy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Online Pharmacy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Retail Pharmacy Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL RETINAL DISORDERS TREATMENT MARKET: BY REGION 2022-2034(USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Type
  • 7.2.2 By Dosage Form
  • 7.2.3 By Distribution Channel
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Type
  • 7.3.2 By Dosage Form
  • 7.3.3 By Distribution Channel
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Type
  • 7.4.2 By Dosage Form
  • 7.4.3 By Distribution Channel
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Type
  • 7.5.2 By Dosage Form
  • 7.5.3 By Distribution Channel
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 South East Asia
  • 7.5.9 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Type
  • 7.6.2 By Dosage Form
  • 7.6.3 By Distribution Channel
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL RETINAL DISORDERS TREATMENT INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 Santen Pharmaceutical Co. Ltd
  • 9.2.2 Regeneron Pharmaceuticals Inc
  • 9.2.3 Graybug Vision Inc
  • 9.2.4 Shire (Takeda Pharmaceutical Company Limited)
  • 9.2.5 Bayer AG
  • 9.2.6 Allergan Plc. (AbbVie Inc.)
  • 9.2.7 Genentech Inc. (F. Hoffmann-La Roche Ltd.)
  • 9.2.8 Acucela Inc
  • 9.2.9 Pfizer Inc
  • 9.2.10 Kubota Pharmaceutical Holdings Co. Ltd